Extended-release buprenorphine in pregnancy

Alexander Hubbell; Ese Aghenta; Cresta W Jones; Sheila Specker

doi:10.1111/ajad.13518

Extended-release buprenorphine in pregnancy

Alexander Hubbell, Ese Aghenta, Cresta W Jones, Sheila Specker

Research output: Contribution to journal › Article › peer-review

Abstract

Background and Objectives: The relative safety and efficacy of monthly extended-release buprenorphine (XR-BUP) has not been fully evaluated in pregnant persons. Methods: Case report of two pregnant individuals receiving XR-BUP while pregnant. Results: Both patients had positive experiences and healthy infants. Discussion and Conclusions: Sparse data regarding the use of XR-BUP in pregnant patients limits shared decision-making. Additional evidence will support the growing population of pregnant patients exposed to XR-BUP. Scientific Significance: Positive patient experiences using XR-BUP during pregnancy have been previously unreported. This report will contribute to discussions of risks and benefits for future patients using XR-BUP during pregnancy.

Original language	English (US)
Journal	American Journal on Addictions
DOIs	https://doi.org/10.1111/ajad.13518
State	Accepted/In press - 2024

Bibliographical note

Publisher Copyright:
© 2024 The Authors. The American Journal on Addictions published by Wiley Periodicals LLC on behalf of The American Academy of Addiction Psychiatry (AAAP).

PubMed: MeSH publication types

Case Reports

Access

10.1111/ajad.13518

Cite this

@article{8dfd956430ce44c587e0738291ba51fc,

title = "Extended-release buprenorphine in pregnancy",

abstract = "Background and Objectives: The relative safety and efficacy of monthly extended-release buprenorphine (XR-BUP) has not been fully evaluated in pregnant persons. Methods: Case report of two pregnant individuals receiving XR-BUP while pregnant. Results: Both patients had positive experiences and healthy infants. Discussion and Conclusions: Sparse data regarding the use of XR-BUP in pregnant patients limits shared decision-making. Additional evidence will support the growing population of pregnant patients exposed to XR-BUP. Scientific Significance: Positive patient experiences using XR-BUP during pregnancy have been previously unreported. This report will contribute to discussions of risks and benefits for future patients using XR-BUP during pregnancy.",

author = "Alexander Hubbell and Ese Aghenta and Jones, {Cresta W} and Sheila Specker",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. The American Journal on Addictions published by Wiley Periodicals LLC on behalf of The American Academy of Addiction Psychiatry (AAAP).",

year = "2024",

doi = "10.1111/ajad.13518",

language = "English (US)",

journal = "American Journal on Addictions",

issn = "1055-0496",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Extended-release buprenorphine in pregnancy

AU - Hubbell, Alexander

AU - Aghenta, Ese

AU - Jones, Cresta W

AU - Specker, Sheila

PY - 2024

Y1 - 2024

N2 - Background and Objectives: The relative safety and efficacy of monthly extended-release buprenorphine (XR-BUP) has not been fully evaluated in pregnant persons. Methods: Case report of two pregnant individuals receiving XR-BUP while pregnant. Results: Both patients had positive experiences and healthy infants. Discussion and Conclusions: Sparse data regarding the use of XR-BUP in pregnant patients limits shared decision-making. Additional evidence will support the growing population of pregnant patients exposed to XR-BUP. Scientific Significance: Positive patient experiences using XR-BUP during pregnancy have been previously unreported. This report will contribute to discussions of risks and benefits for future patients using XR-BUP during pregnancy.

AB - Background and Objectives: The relative safety and efficacy of monthly extended-release buprenorphine (XR-BUP) has not been fully evaluated in pregnant persons. Methods: Case report of two pregnant individuals receiving XR-BUP while pregnant. Results: Both patients had positive experiences and healthy infants. Discussion and Conclusions: Sparse data regarding the use of XR-BUP in pregnant patients limits shared decision-making. Additional evidence will support the growing population of pregnant patients exposed to XR-BUP. Scientific Significance: Positive patient experiences using XR-BUP during pregnancy have been previously unreported. This report will contribute to discussions of risks and benefits for future patients using XR-BUP during pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=85183029214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85183029214&partnerID=8YFLogxK

U2 - 10.1111/ajad.13518

DO - 10.1111/ajad.13518

M3 - Article

C2 - 38264845

AN - SCOPUS:85183029214

SN - 1055-0496

JO - American Journal on Addictions

JF - American Journal on Addictions

ER -

Extended-release buprenorphine in pregnancy

Abstract

Bibliographical note

PubMed: MeSH publication types

Access

Other files and links

Fingerprint

Cite this